ATE283279T1 - Therapeutische inhaltsstoffe - Google Patents

Therapeutische inhaltsstoffe

Info

Publication number
ATE283279T1
ATE283279T1 AT94915474T AT94915474T ATE283279T1 AT E283279 T1 ATE283279 T1 AT E283279T1 AT 94915474 T AT94915474 T AT 94915474T AT 94915474 T AT94915474 T AT 94915474T AT E283279 T1 ATE283279 T1 AT E283279T1
Authority
AT
Austria
Prior art keywords
antagonists
biologically
peptides
therapeutic ingredients
pharmaceutical compositions
Prior art date
Application number
AT94915474T
Other languages
English (en)
Inventor
Ahmed Abdullah Azad
Cyril C Curtain
A Greenway
D A Mcphee
Ian Macreadie
Original Assignee
Macfarlane Burnet Ct For Medic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macfarlane Burnet Ct For Medic filed Critical Macfarlane Burnet Ct For Medic
Application granted granted Critical
Publication of ATE283279T1 publication Critical patent/ATE283279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94915474T 1993-05-18 1994-05-18 Therapeutische inhaltsstoffe ATE283279T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL886193 1993-05-18
PCT/AU1994/000254 WO1994026776A1 (en) 1993-05-18 1994-05-18 Therapeutic compounds

Publications (1)

Publication Number Publication Date
ATE283279T1 true ATE283279T1 (de) 2004-12-15

Family

ID=3776902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915474T ATE283279T1 (de) 1993-05-18 1994-05-18 Therapeutische inhaltsstoffe

Country Status (7)

Country Link
US (2) US5962635A (de)
EP (1) EP0717752B1 (de)
JP (1) JP3699112B2 (de)
AT (1) ATE283279T1 (de)
CA (1) CA2163212C (de)
DE (1) DE69434151D1 (de)
WO (1) WO1994026776A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112636A0 (en) * 1994-02-14 1995-05-26 Macfarlane Burnet Ctre Med Res Non-pathogenic strains of hiv-1
WO1998013377A1 (en) * 1996-03-06 1998-04-02 Biomolecular Research Institute Ltd. Cytotoxic peptides
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
CN100471956C (zh) * 2001-03-09 2009-03-25 基因流股份有限公司 新型表达载体
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2420248A1 (de) * 2004-08-17 2012-02-22 Institut Gustave Roussy Mutiertes HIV-NEF zur Immunitätsmodulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0349354A1 (de) * 1988-04-01 1990-01-03 Institut Pasteur Peptide PF10 bis PF19 von einem Retrovirus HIV, Verfahren zur Synthese dieser Peptide und ihre Verwendung, insbesondere zur Diagnose
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
CA2135646A1 (en) * 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
GB9311043D0 (en) * 1993-05-28 1993-07-14 Medical Res Council Inhibitors of nef-cd4 binding

Also Published As

Publication number Publication date
EP0717752A4 (de) 1997-08-20
CA2163212C (en) 2004-07-13
CA2163212A1 (en) 1994-11-24
DE69434151D1 (de) 2004-12-30
JP3699112B2 (ja) 2005-09-28
US6197583B1 (en) 2001-03-06
EP0717752A1 (de) 1996-06-26
JPH09501143A (ja) 1997-02-04
EP0717752B1 (de) 2004-11-24
WO1994026776A1 (en) 1994-11-24
US5962635A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE549028T1 (de) Stabile analoga von glp-1
NO952744D0 (no) Cytokinbegrensende midler
RU95115239A (ru) Аналог эритропоэтина
ATE165100T1 (de) Peptide mit endothelin antagonistischer aktivität, deren herstellung und pharmazeutische zusammensetzungen
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE60225118D1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
MA26502A1 (fr) Analogues peptidiques de la lh-rh, leur utilisation et les compositions pharmaceutiques les contenant.
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
NL300830I2 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
BG104266A (en) Aminoterminally incised mcp-2 as haemokin antagonists
EP1641824A4 (de) Analoga von peptiden der relaxin-superfamilie
ES2171086T3 (es) Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.
DE69520092D1 (de) Hochaktive VIP - Antagonisten
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE69434151D1 (de) Therapeutische inhaltsstoffe
CA2181590A1 (en) Peptomers with enhanced immunogenicity
GB9311454D0 (en) Pharmaceutical compositions
ATE42308T1 (de) Pharmakologisch aktive peptide.
DE69738600D1 (de) Neuroaktive peptide
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
EP0656010B8 (de) Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties